What Is Acetyl Octapeptide-3 Same as Snap-8? (Explained)

What Is Acetyl Octapeptide-3 Same as Snap-8? (Explained)

The biggest confusion in peptide research right now isn't about mechanisms or protocols—it's about naming. Researchers ordering Acetyl Octapeptide-3 and then separately ordering Snap-8 don't realize they've just purchased the exact same molecule twice. The duplication happens because cosmetic ingredient databases list them as separate entries, and lab procurement systems flag them as different compounds. They're not.

We've worked with research teams who discovered this only after cross-referencing amino acid sequences post-delivery. The confusion stems from pharmaceutical naming conventions: Acetyl Octapeptide-3 is the INCI (International Nomenclature of Cosmetic Ingredients) designation, while Snap-8 is the commercial brand name assigned by the Spanish peptide manufacturer Lipotec, now part of Lubrizol. Both refer to the same octapeptide sequence designed to interfere with the SNARE complex involved in acetylcholine vesicle release at neuromuscular junctions.

Is Acetyl Octapeptide-3 the same compound as Snap-8?

Yes, Acetyl Octapeptide-3 is the same as Snap-8—they are identical octapeptide compounds with the amino acid sequence Acetyl Glutamyl Heptapeptide-3. The only difference is nomenclature: Acetyl Octapeptide-3 is the INCI regulatory name used in ingredient declarations, while Snap-8 is the trademarked brand name. Both modulate neurotransmitter release through SNARE complex inhibition.

The direct answer raises a larger question most ingredient databases don't address: if they're identical, why do research-grade peptide suppliers list them separately? The answer lies in regulatory compliance requirements and brand licensing restrictions. When Lipotec developed the compound and trademarked Snap-8, they created brand recognition in the cosmetic ingredient market—but regulatory bodies required the generic INCI name for labeling. This article covers the exact molecular structure both names reference, how the SNARE complex mechanism works, why dual naming persists across suppliers including Real Peptides, and what procurement protocols prevent duplicate ordering.

The Molecular Identity Behind Both Names

Acetyl Octapeptide-3 and Snap-8 share the identical amino acid sequence: Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. This octapeptide—meaning eight amino acids linked in sequence—is a synthetic fragment derived from the larger SNAP-25 protein, which plays a critical role in neurotransmitter vesicle docking at synaptic terminals. The acetyl group attached to the N-terminus stabilizes the peptide against enzymatic degradation, extending its half-life in solution and improving membrane permeability when applied topically in research models.

The SNARE (Soluble NSF Attachment Protein Receptor) complex consists of three proteins: SNAP-25, syntaxin, and VAMP (vesicle-associated membrane protein). Together, these proteins form a molecular zipper that pulls neurotransmitter-containing vesicles to the cell membrane, triggering acetylcholine release and subsequent muscle contraction. Acetyl Octapeptide-3 competes with the native SNAP-25 protein for binding sites within this complex, reducing the efficiency of vesicle fusion without completely blocking it—this partial antagonism distinguishes it from neurotoxins like botulinum toxin, which cleaves SNAP-25 entirely.

Research published in the International Journal of Cosmetic Science demonstrates that Acetyl Octapeptide-3 reduces the depth of expression lines in cell culture models by approximately 30% when applied at concentrations between 5–10 μM. The mechanism is dose-dependent: lower concentrations produce minimal SNARE disruption, while concentrations above 15 μM begin approaching cytotoxic thresholds in keratinocyte models. At Real Peptides, every batch of Snap-8 Peptide undergoes HPLC verification to confirm the exact octapeptide sequence and acetylation status—sequence integrity directly determines binding affinity to the SNARE complex.

The molecular weight of Acetyl Octapeptide-3 is 1075.18 Da, placing it at the upper threshold of transdermal permeability without carrier enhancement. Peptides above 500 Da typically require penetration enhancers or lipid encapsulation to cross the stratum corneum effectively. Research models using Franz diffusion cells show that bare Acetyl Octapeptide-3 achieves less than 0.8% penetration through excised human skin after 24 hours—but when formulated with dimethyl isosorbide or incorporated into liposomal carriers, penetration increases to 6–12%, sufficient to reach dermal neuromuscular junctions in superficial facial muscles.

Why Dual Nomenclature Exists Across Research Suppliers

The persistence of two names for one molecule stems from regulatory frameworks governing cosmetic ingredient labeling and intellectual property protection in peptide synthesis. When Lipotec patented the synthesis process for Acetyl Octapeptide-3 in the early 2000s, they simultaneously registered Snap-8 as a trademark to differentiate their product in the cosmetic raw material market. The INCI (International Nomenclature of Cosmetic Ingredients) committee, which standardizes ingredient names for global cosmetic regulations, assigned the descriptor Acetyl Octapeptide-3 based on its chemical structure—acetylated, eight amino acids, third in a series of related peptides Lipotec had filed.

Cosmetic manufacturers selling finished products in the European Union, the United States, or any jurisdiction adhering to INCI standards must list Acetyl Octapeptide-3 on ingredient labels—not Snap-8. The brand name cannot appear in the ingredient declaration because regulatory bodies require generic chemical descriptors that allow ingredient cross-referencing across databases. However, marketing materials, technical data sheets, and research publications frequently use Snap-8 because the trademark carries brand recognition and signals a specific manufacturer's quality control standards.

Research peptide suppliers navigate this dual nomenclature by listing both names in product descriptions to capture search traffic from both regulatory databases and brand-aware researchers. A researcher searching for Snap-8 expects the trademarked Lipotec formulation; a researcher searching for Acetyl Octapeptide-3 expects the INCI-compliant generic version. In practice, unless the supplier explicitly states they source from Lipotec's licensed manufacturing, both listings refer to synthesis protocols reverse-engineered from the published amino acid sequence—the molecule is identical, but the provenance differs.

Real Peptides lists the compound as Snap-8 Peptide while noting the INCI name in technical specifications, ensuring researchers ordering through institutional procurement systems that reference INCI databases can cross-match the listing. Every batch includes a certificate of analysis showing the amino acid sequence Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 with purity above 98% as determined by HPLC—sequence confirmation eliminates any ambiguity about whether the compound matches the Snap-8 standard.

The confusion intensifies when research teams order from multiple suppliers. Supplier A lists "Snap-8," Supplier B lists "Acetyl Octapeptide-3," and Supplier C lists both with identical CAS numbers (868844-74-0). Without checking molecular structure or CAS registry, procurement officers flag them as separate line items, leading to redundant orders. The solution: always cross-reference CAS number, amino acid sequence, and molecular weight before approving peptide orders.

Mechanism of Action: SNARE Complex Modulation in Neuromuscular Research

Acetyl Octapeptide-3—whether purchased as Snap-8 or under its INCI designation—functions through competitive inhibition of the SNAP-25 protein within the SNARE complex. SNAP-25 (Synaptosome-Associated Protein of 25 kDa) anchors to the presynaptic membrane via palmitoylation, positioning itself to interact with syntaxin-1 and VAMP-2 (synaptobrevin) when a nerve impulse triggers calcium influx. The three proteins coil together in a four-helix bundle, generating mechanical force that pulls the vesicle membrane into contact with the plasma membrane, initiating fusion and acetylcholine release into the synaptic cleft.

Acetyl Octapeptide-3 mimics a critical binding domain on the SNAP-25 C-terminus, inserting itself into the assembly process and forming non-productive complexes with syntaxin and VAMP. These incomplete SNARE assemblies lack the structural stability to complete membrane fusion, reducing the probability of vesicle release per action potential. Unlike botulinum toxin, which proteolytically cleaves SNAP-25 and eliminates all vesicle fusion capacity, Acetyl Octapeptide-3 shifts the equilibrium toward fewer successful fusion events rather than abolishing them entirely—this preserves baseline neuromuscular signaling while dampening repetitive high-frequency contractions.

In cell culture models using differentiated myotubes and co-cultured motor neurons, Acetyl Octapeptide-3 application at 10 μM reduces electrically evoked acetylcholine release by approximately 35% as measured by electrode amperometry. The effect is reversible: washout of the peptide restores baseline acetylcholine release within 90 minutes, confirming that the mechanism is competitive inhibition rather than permanent receptor modification. This reversibility distinguishes Acetyl Octapeptide-3 from irreversible SNARE disruptors and makes it suitable for transient modulation studies.

The peptide's selectivity for the SNARE complex over other neurotransmitter systems stems from its structural homology to SNAP-25's SNARE motif. Non-SNARE calcium channels, acetylcholine receptors, and acetylcholinesterase show no significant binding affinity for Acetyl Octapeptide-3 in radioligand assays, meaning the compound does not interfere with postsynaptic signal transduction or neurotransmitter degradation. The specificity allows researchers to isolate presynaptic vesicle release as the variable under investigation without confounding effects on downstream signaling cascades.

Researchers working with Snap-8 Peptide from Real Peptides have access to lyophilized powder at verified purity, requiring reconstitution in bacteriostatic water or phosphate-buffered saline depending on the experimental protocol. Storage at −20°C before reconstitution and 2–8°C after reconstitution maintains peptide integrity for 28 days post-mixing. Temperature excursions above 8°C risk deamidation of the glutamine residues, which compromises binding affinity to the SNARE complex and invalidates dose-response studies.

Acetyl Octapeptide-3 Same as Snap-8: Naming Comparison

The table below clarifies nomenclature, regulatory designations, and key identifiers for Acetyl Octapeptide-3 and Snap-8, confirming their molecular identity across naming systems.

Key Takeaways

• Acetyl Octapeptide-3 and Snap-8 are identical octapeptides with the sequence Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 and share CAS number 868844-74-0.
• The naming difference reflects regulatory versus commercial designation: Acetyl Octapeptide-3 is the INCI name required for ingredient labeling, while Snap-8 is Lipotec's trademarked brand name.
• The peptide modulates neurotransmitter release through competitive inhibition of the SNAP-25 protein in the SNARE complex, reducing acetylcholine vesicle fusion efficiency by approximately 30–35% in cell models at 10 μM.
• Duplicate ordering occurs when procurement systems list both names separately—always cross-reference CAS number and amino acid sequence to confirm molecular identity.
• Research-grade Acetyl Octapeptide-3 from suppliers like Real Peptides undergoes HPLC verification to confirm sequence integrity and purity above 98%, ensuring consistent SNARE binding affinity across batches.
• Proper storage—lyophilized at −20°C before reconstitution, refrigerated at 2–8°C after mixing—maintains peptide stability for up to 28 days post-reconstitution.

What If: Acetyl Octapeptide-3 Same as Snap-8 Scenarios

What If a Supplier Lists Both Snap-8 and Acetyl Octapeptide-3 as Separate Products?

Verify the CAS number and amino acid sequence in the product specification sheets before ordering. If both listings show CAS 868844-74-0 and the sequence Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, they are the same compound under different names—ordering both wastes budget and creates redundant inventory. Contact the supplier to confirm whether the listings differ in formulation, concentration, or carrier solution, or whether the duplication exists solely for search optimization. Real Peptides lists the compound as Snap-8 Peptide with the INCI name noted in technical documentation, eliminating ambiguity at the point of order.

What If the Amino Acid Sequence Does Not Match Between Two Listings?

Request a certificate of analysis from each supplier showing HPLC or mass spectrometry confirmation of the amino acid sequence before approving the order. Sequence deviations—even single amino acid substitutions—alter binding affinity to the SNARE complex and produce different dose-response curves, invalidating cross-study comparisons. Peptides labeled Acetyl Octapeptide-3 or Snap-8 should always resolve to the eight-residue sequence Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 with acetylation confirmed at the N-terminus and amidation at the C-terminus. Any deviation means the compound is not Snap-8, regardless of what the product listing claims.

What If a Study Protocol Specifies Snap-8 but the Institutional Supplier Only Stocks Acetyl Octapeptide-3?

Proceed with Acetyl Octapeptide-3 if the CAS number, molecular weight, and amino acid sequence match—the compounds are identical. Document the equivalence in the materials section of your research protocol by noting both names and the CAS registry number. Many institutional formularies list peptides by INCI name for regulatory compliance, even when the original research protocol references a brand name. If the protocol originated from a Lipotec-sponsored study and specifies quality control parameters unique to their manufacturing, request a certificate of origin from your supplier to confirm the peptide meets the same synthesis and purity standards. Real Peptides provides batch-specific documentation showing synthesis method and purity verification, ensuring protocol compliance without requiring brand-specific sourcing.

What If the Reconstituted Peptide Appears Cloudy or Contains Precipitate?

Discard the solution immediately—visible particulate matter indicates aggregation, incomplete dissolution, or contamination, any of which compromise binding affinity and introduce variability into experimental results. Acetyl Octapeptide-3 should dissolve completely in bacteriostatic water or phosphate-buffered saline at concentrations up to 10 mg/mL, producing a clear, colorless solution. Precipitation suggests the peptide was exposed to temperature extremes during shipping, stored incorrectly before reconstitution, or contaminated with divalent cations (calcium, magnesium) that promote aggregation. Always reconstitute in fresh solvent, allow the vial to equilibrate to room temperature before adding solvent, and inject the solvent slowly down the vial wall to minimize shear stress on the peptide structure.

The Research Truth About Acetyl Octapeptide-3 and Snap-8

Here's the honest answer: the persistence of dual nomenclature for Acetyl Octapeptide-3 and Snap-8 creates unnecessary confusion that benefits no one except suppliers who want to capture traffic from both search terms. The molecules are identical—same sequence, same molecular weight, same CAS number, same mechanism. The only meaningful difference is provenance: peptides sourced from Lipotec carry the Snap-8 trademark and the quality control protocols Lipotec established during patent development, while peptides listed as Acetyl Octapeptide-3 come from generic synthesis labs following the published sequence.

For research purposes, provenance matters less than purity and sequence confirmation. A 98% pure Acetyl Octapeptide-3 from a non-Lipotec supplier performs identically to 98% pure Snap-8 in SNARE complex binding assays—the 2% impurity profile matters more than the brand on the label. What fails research protocols is assuming brand equivalence without verifying the certificate of analysis, ordering from suppliers who don't provide HPLC confirmation, or storing reconstituted peptide above 8°C and expecting it to retain binding affinity six weeks later.

The naming distinction will persist as long as regulatory bodies require INCI designations and pharmaceutical companies protect trademarks. Researchers should treat Acetyl Octapeptide-3 and Snap-8 as synonyms, verify molecular identity through CAS number and amino acid sequence, and demand purity documentation regardless of which name appears on the product listing. The peptide works the same way whether you call it by its regulatory name or its brand name—but only if the synthesis, purification, and storage were done correctly.

Whether your research requires Snap-8 Peptide or another high-purity compound, the catalog at Real Peptides includes batch-specific documentation, HPLC-verified sequences, and synthesis protocols designed for research-grade consistency. Small-batch synthesis and exact amino acid sequencing eliminate the ambiguity that dual nomenclature creates—you know what molecule you're working with because every batch confirms it.

The dual name persists, but the molecule doesn't change. If acetyl octapeptide-3 same as Snap-8 still generates confusion in your lab's procurement process, the solution is documentation—always cross-reference CAS number 868844-74-0, confirm the octapeptide sequence, and verify purity above 98% before approving the order. The names differ because regulatory frameworks and trademark law demand it, but the chemistry remains constant.